Association between SARS-CoV-2 exposure and antibody status among healthcare workers in two London hospitals: a cross-sectional study.
Coronavirus
Covid-19
Health-care workers
Risk
Sars-cov-2
Serology
Journal
Infection prevention in practice
ISSN: 2590-0889
Titre abrégé: Infect Prev Pract
Pays: England
ID NLM: 101777928
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
30
03
2021
accepted:
15
06
2021
entrez:
28
7
2021
pubmed:
29
7
2021
medline:
29
7
2021
Statut:
ppublish
Résumé
Patient-facing (frontline) health-care workers (HCWs) are at high risk of repeated exposure to SARS-CoV-2. We sought to determine the association between levels of frontline exposure and likelihood of SARS-CoV-2 seropositivity amongst HCW. A cross-sectional study was undertaken using purposefully collected data from HCWs at two hospitals in London, United Kingdom (UK) over eight weeks in May-June 2020. Information on sociodemographic, clinical and occupational characteristics was collected using an anonymised questionnaire. Serology was performed using split SARS-CoV-2 IgM/IgG lateral flow immunoassays. Exposure risk was categorised into five pre-defined ordered grades. Multivariable logistic regression was used to examine the association between being frontline and SARS-CoV-2 seropositivity after controlling for other risks of infection. 615 HCWs participated in the study. 250/615 (40.7%) were SARS-CoV-2 IgM and/or IgG positive. After controlling for other exposures, there was non-significant evidence of a modest association between being a frontline HCW (any level) and SARS-CoV-2 seropositivity compared to non-frontline status (OR 1.39, 95% CI 0.84-2.30, We found a high SARS-CoV-2 IgM/IgG seropositivity with modest evidence for a dose-response association between increasing levels of frontline exposure risk and seropositivity. Even in well-resourced hospital settings, appropriate use of personal protective equipment, in addition to other transmission-based precautions for inpatient care of SARS-CoV-2 patients could reduce the risk of hospital-acquired SARS-CoV-2 infection among frontline HCW.
Sections du résumé
BACKGROUND
BACKGROUND
Patient-facing (frontline) health-care workers (HCWs) are at high risk of repeated exposure to SARS-CoV-2.
AIM
OBJECTIVE
We sought to determine the association between levels of frontline exposure and likelihood of SARS-CoV-2 seropositivity amongst HCW.
METHODS
METHODS
A cross-sectional study was undertaken using purposefully collected data from HCWs at two hospitals in London, United Kingdom (UK) over eight weeks in May-June 2020. Information on sociodemographic, clinical and occupational characteristics was collected using an anonymised questionnaire. Serology was performed using split SARS-CoV-2 IgM/IgG lateral flow immunoassays. Exposure risk was categorised into five pre-defined ordered grades. Multivariable logistic regression was used to examine the association between being frontline and SARS-CoV-2 seropositivity after controlling for other risks of infection.
FINDINGS
RESULTS
615 HCWs participated in the study. 250/615 (40.7%) were SARS-CoV-2 IgM and/or IgG positive. After controlling for other exposures, there was non-significant evidence of a modest association between being a frontline HCW (any level) and SARS-CoV-2 seropositivity compared to non-frontline status (OR 1.39, 95% CI 0.84-2.30,
CONCLUSION
CONCLUSIONS
We found a high SARS-CoV-2 IgM/IgG seropositivity with modest evidence for a dose-response association between increasing levels of frontline exposure risk and seropositivity. Even in well-resourced hospital settings, appropriate use of personal protective equipment, in addition to other transmission-based precautions for inpatient care of SARS-CoV-2 patients could reduce the risk of hospital-acquired SARS-CoV-2 infection among frontline HCW.
Identifiants
pubmed: 34316587
doi: 10.1016/j.infpip.2021.100157
pii: S2590-0889(21)00046-9
pmc: PMC8217738
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100157Informations de copyright
© 2021 Published by Elsevier Ltd on behalf of The Healthcare Infection Society.
Références
Nat Commun. 2020 Jul 8;11(1):3500
pubmed: 32641730
Lancet Infect Dis. 2020 Dec;20(12):1401-1408
pubmed: 32758438
Nat Commun. 2020 Oct 8;11(1):5064
pubmed: 33033249
Clinics (Sao Paulo). 2020;75:e2212
pubmed: 32785570
Lancet. 2020 Jul 25;396(10246):e6-e7
pubmed: 32653078
J Gen Intern Med. 2020 Aug;35(8):2485-2486
pubmed: 32495088
J Hosp Infect. 2020 Sep;106(1):102-106
pubmed: 32593608
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1221-1226
pubmed: 32881855
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Lancet Respir Med. 2020 Sep;8(9):885-894
pubmed: 32717210
BMC Pulm Med. 2020 Jul 29;20(1):203
pubmed: 32727446
Occup Med (Lond). 2020 Mar 12;70(1):3-5
pubmed: 32107548
Thorax. 2020 Dec;75(12):1089-1094
pubmed: 32917840
Anal Chem. 2020 Aug 4;92(15):10196-10209
pubmed: 32573207
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Am J Epidemiol. 2021 Jan 4;190(1):161-175
pubmed: 32870978
Int J Infect Dis. 2020 Oct;99:219-225
pubmed: 32758693
Nat Commun. 2021 Feb 10;12(1):905
pubmed: 33568663
JAMA. 2020 Sep 1;324(9):893-895
pubmed: 32780804
Infect Control Hosp Epidemiol. 2021 Apr;42(4):392-398
pubmed: 32962771
Antimicrob Resist Infect Control. 2020 Jun 11;9(1):83
pubmed: 32527300
Rev Soc Bras Med Trop. 2020;53:e20200458
pubmed: 32876319
J Med Virol. 2020 Sep;92(9):1518-1524
pubmed: 32104917
J Hosp Infect. 2021 Feb;108:120-134
pubmed: 33212126
Anaesthesia. 2020 Dec;75(12):1614-1619
pubmed: 32777861
Infection. 2020 Aug;48(4):631-634
pubmed: 32524515
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512